Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADS-5102 in MS walking impairment
NCT02471222Phase 2Completed
- Start
- May 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing ADS-5102 with Placebo (2 arms). Primary endpoint: Safety of ADS-5102 at 4 weeks. Started May 2015; status: completed.
02
Drugs
amantadine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02471222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471222.